Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03307122
Other study ID # 17.01.US.INF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 21, 2017
Est. completion date January 19, 2018

Study information

Verified date May 2018
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, double-blind, randomized study of 2 infant formulas.


Description:

Exclusively formula-fed infants will participate in a 6-week feeding period of an infant formula. Tolerance records will be kept for 2 days at the end of the 6-week period by caregivers.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date January 19, 2018
Est. primary completion date January 19, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 19 Days
Eligibility Inclusion Criteria:

- Healthy newborn singleton infant

- Full-term (> 37 weeks gestation)

- Birth weight = 2500 grams and = 4500 grams

- 9-19 days of age on enrollment

- Infant's mother has elected not to breastfeed prior to enrollment and infant has exclusively formula-fed for at least 3days prior to enrollment

- Having obtained his/her legal representative's informed consent

Exclusion Criteria:

- Known or suspected cow-milk allergy

- Currently receiving a specialty infant formula (e.g. extensively hydrolyzed, amino acid-based, metabolic), or soy-based or lactose free infant formula

- Currently not tolerating (as perceived by the caregiver) their formula

- Currently being treated for reflux

- Currently experiencing gastrointestinal or respiratory symptoms secondary to an on-going infection or virus (e.g. gastrointestinal infection, upper respiratory infection, flu)

- Congenital illness or malformation that may affect infant feeding and/or growth

- Any readmission to hospital (except for hyperbilirubinemia) prior to enrollment

- Receiving prescription medication (with exception of treatment for thrush or topical medications) or home remedies, herbal preparations, or rehydration fluids that might affect GI tolerance (vitamin and mineral supplements excepted).

- Infant's family who in the Investigator's assessment cannot be expected to comply with treatment (feeding regimen).

- Participation in another study that has not been approved as a concomitant study by Nestlé Nutrition.

Study Design


Related Conditions & MeSH terms

  • Healthy, Full-term Infants Who Are Formula-fed

Intervention

Other:
Routine Infant Formula 1
Routine infant formula with probiotic
Routine Infant Formula 2
Routine infant formula with probiotic and prebiotic

Locations

Country Name City State
United States Coastal Pediatric Associates Charleston South Carolina
United States Ohio Pediatric Research Association Dayton Ohio
United States Tanner Clinic Layton Utah
United States Bluegrass Clinical Research, Inc. Louisville Kentucky
United States Midsouth Center for Clinical Research, LLC Memphis Tennessee
United States PediaResearch Owensboro Kentucky
United States Avanza Medical Research Center Pensacola Florida
United States Southwest Children's Research Associates San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Infant GI Symptom Burden Study personnel will administer questionnaire 6 weeks
Secondary Stool pattern Caregivers will document on diary records 6 weeks
Secondary Spit-up and/or vomiting pattern Caregivers will document on diary records 6 weeks
Secondary Crying and fussing duration Caregivers will document on diary records 6 weeks
Secondary Formula intake Caregivers will document on diary records 6 weeks
Secondary Formula satisfaction questionnaire Study personnel will administer questionnaire 6 weeks
Secondary Weight (measured in grams) Study personnel will measure Enrollment and 6 weeks
Secondary Length (measured in centimeters) Study personnel will measure Enrollment and 6 weeks
Secondary Adverse events Assessed throughout study 2 weeks and 6 weeks